Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Inspire Pharmaceuticals wins award for its denufosol tetrasodium program

Inspire Pharmaceuticals, Inc. announced today it received the North Carolina Health & Life Sciences Award in the category of “Breakthrough Research” for its denufosol tetrasodium program for cystic fibrosis (CF).

9 Sep 2009

Biogen Idec restates its plan to purchase all outstanding shares of Facet Biotech

Biogen Idec Inc. today reiterated its proposal to acquire all of the outstanding shares of Facet Biotech Corporation for $14.50 per share in cash.

9 Sep 2009

Teva Pharmaceutical Industries to present MS treatment research data

Teva Pharmaceutical Industries Ltd. today announced that new research data furthering the clinical understanding of its diverse multiple sclerosis (MS) treatment franchise will be presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany, September 9-12, 2009.

9 Sep 2009

Opexa Therapeutics' ongoing development program for Tovaxin to be presented

Opexa Therapeutics, Inc., a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexa’s president and chief executive officer, will deliver a corporate presentation at Rodman & Renshaw’s 11th Annual Healthcare Conference.

8 Sep 2009

Opexa Therapeutics releases Phase IIb TERMS clinical study results

Opexa Therapeutics, Inc., a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced results from further analysis of the double-blind, placebo-controlled, 52-week Phase IIb TERMS clinical study of 150 patients with Relapsing Remitting MS (RRMS).

8 Sep 2009

RONA MS Bike Tour organized for the benefit of the Quebec Division of the MS Society a huge success

The 20th edition of the RONA MS Bike Tour, organized for the benefit of the Quebec Division of the Multiple Sclerosis Society of Canada, ended last weekend in a glow of unbelievable generosity. Together, the 1,500 cyclists raised $1,450,000, which will fund research and services for people with multiple sclerosis (MS) and their families. Participants got together in the Victoriaville area on August 22 and 23, and in the Levis region on August 29 and 30.

8 Sep 2009

Scientists solve the mystery of zonulin's identity

It was nine years ago that University of Maryland School of Medicine researchers discovered that a mysterious human protein called zonulin played a critical role in celiac disease and other autoimmune disorders, such as multiple sclerosis and diabetes.

8 Sep 2009

PPA bus tour raises awareness of patient assistance programs

The "Help is Here Express" bus tour will be stopping in Kentucky throughout the week of September 8 - 11 at various cities in order to help uninsured and financially-struggling Kentuckians access information on programs that provide prescription medicines for free or nearly free.

5 Sep 2009

Biogen Idec offers to completely acquire Facet

Biogen Idec’s interest in acquiring Facet was first conveyed on August 17, 2009 by Mr. Mullen to Faheem Hasnain, President and Chief Executive Officer of Facet.

5 Sep 2009

HTDS announces closure of Regulation D 504 offering

Hard to Treat Diseases (the "Company") (HTDS.PK) announced today that it has closed its Regulation D, Rule 504 offering and is no longer selling shares of its common stock to accredited investors.

4 Sep 2009

Positive impact on medication adherence through Aetna's care management program

Aetna announced today results of an analysis from the first half of 2009, demonstrating an average medication adherence of over 95 percent for its members taking Specialty medications. Disease states evaluated in Aetna’s analysis include: multiple sclerosis, rheumatoid arthritis, HIV, Crohn's disease, Pulmonary Arterial Hypertension (PAH), psoriasis, Hepatitis C and asthma.

4 Sep 2009

Medtronic's COPE-HCV clinical study commences

Medtronic, Inc., today reported the initiation and first enrollments of patients in COPE-HCV (COntinuous Interferon Delivery via the Medtronic Paradigm Pump Infusion System Clinical Evaluation for Chronic HCV), the company’s first-ever clinical study using an external pump infusion system to treat patients with the hepatitis C virus (HCV).

3 Sep 2009

Biogen Idec's MS franchise to present at the 25th Congress of ECTRIMS

Biogen Idec today announced more than 70 platform and poster presentations from the company’s multiple sclerosis (MS) franchise being presented during the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany.

3 Sep 2009

BioMS Medical update on dirucotide development

BioMS Medical Corp. (TSX: MS), today provided an update on developments in respect of dirucotide, its drug candidate for multiple sclerosis (MS).

2 Sep 2009

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA’s Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar’s efficacy and safety in the proposed patient population.

2 Sep 2009

SAGE forges agreement with the International Headache Society

SAGE, the world's leading independent academic and professional publisher is delighted to announce a new agreement with the International Headache Society (IHS) to publish their official journal, Cephalalgia.

2 Sep 2009

Rapid progression of multiple sclerosis linked to smoking

Patients with multiple sclerosis who smoke appear to experience a more rapid progression of their disease, according to a report in the July issue of Archives of Neurology, one of the JAMA/Archives journals.

2 Sep 2009

T cells influence aggressive immune cells by regulating the chemical environment between cells

University of Michigan scientists say they have uncovered a fundamentally new mechanism that holds in check aggressive immune cells that can attack the body's own cells. The findings open a new avenue of research for future therapies for conditions ranging from autoimmune diseases to organ transplants to cancer.

2 Sep 2009

White matter hyperintensities could lead to permanent thinking problems

Elderly people with no memory or thinking problems are more likely to later develop thinking problems if they have a growing amount of "brain rust," or small areas of brain damage, according to a study published in the July 14, 2009, print issue of NeurologyÂ®, the medical journal of the American Academy of Neurology.

2 Sep 2009

Cigarettes and not Swedish snuff increase the risk of developing multiple sclerosis

While smoking cigarettes appears to significantly increase a person's risk of developing multiple sclerosis, using Swedish snuff does not, according to a study published in the September 1, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

1 Sep 2009